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NC-ABSTRACT
Medical devices provide people with some health benefits in terms of diagnosis, prevention,
treatment, and monitoring of disease processes. Different medical specialties use varieties of
medical devices more or less specific for them. Allergology is an interdisciplinary field of medical
science and teaches that allergic reactions are of systemic nature but can express themselves at
the level of different organs across the life cycle of an individual. Subsequently, medical devices
used in allergology could be regarded as: 1) general, servicing the integral diagnostic and man-
agement principles and features of allergology, and 2) organ specific, which are shared by organ
specific disciplines like pulmonology, otorhinolaryngology, dermatology, and others. The present
position paper of the World Allergy Organization (WAO) is meant to be the first integral document
providing structured information on medical devices in allergology used in daily routine but also
needed for sophisticated diagnostic purposes and modern disease management. It is supposed to
contribute to the transformation of the health care system into integrated care pathways for
interrelated comorbidities.
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function tests, m-health, Airway inflammation, Allergic rhinitisINTRODUCTION
The simple and straight forward definition of a
medical device is any device intended to be used
for medical purposes. Based on that, there are a
myriad of items which fall within this scope and are
used for diagnostic or disease management pur-
poses. A broader general feature that renders
devices "medical" is that they provide people with
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differ by way of the medical field they are used in;
or, changing the perspective, the different
branches of medicine make use of a variety of
medical devices more or less specific for them. As
most clinical disciplines derive their names from
one or more related organs they are specialized in,
the associated medical devices are also organ-
specific in most cases.
Allergology is an interdisciplinary field of med-
ical science and teaches that allergic reactions are
of systemic nature but can express themselves at
the level of different organs across the life cycle of
an individual. Subsequently, medical devices used
in allergology could be regarded as: 1) general,
servicing the integral diagnostic and management
principles and features of allergology, and 2) or-
gan specific, which are shared by the corre-
sponding organ-specific disciplines like
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and others (Table 1). Alternatively, medical devices
in allergy practice may be classified in terms of the
specific pathologic features of the conditions for
which they are applied (Table 2).
What is a “medical device” and what is not
There is a fine line of distinction between med-
ical devices on the one hand, and any other ob-
jects, instruments, foods, and auxiliary substances
used in everyday life or in healthcare on the other.
While it is clear that scissors on the office desk
are not the medical device “scissors” in surgical
practice, the difference between medical devices
and other products in many other cases may be
more obscure. Thus, pharmaceutical formulations
fall outside the scope of medical devices despite
being used for medical purposes: they contain
biologically active compounds which are the result
of long meticulous development and need to pass
rigid scrutiny for efficacy and safety of the licensing
authorities. At the same time, natural products and
food additives follow a different track of develop-
ment and control and are classified as medical
devices.
Similarly to pharmaceutical products, laboratory
tests are not considered medical devices and are
not covered by this overview.
Depending on the health risks they pose, med-
ical devices are categorized into 3 types and
respective subtypes. The US Food and Drug
Administration (FDA) categorizes medical devices
into 1 of 3 classes – Class I, II, or III – based on their
risks and the regulatory controls necessary to
provide a reasonable assurance of safety and
effectiveness.1 Class I devices generally pose the
lowest risk to the patient and/or user, and Class
III devices pose the highest risk. In Europe,
medical devices are usually regulated by national
competent authorities, but the European
Medicines Agency (EMA) is also involved in
regulating some categories of medical devices in
accordance with the recently European Union
legislation (Regulation EU 2017/745 on Medical
Devices and Regulation EU 2017/746 on In vitro
Diagnostic Medical Devices). These regulations,
issued in 2017, will be fully applied after a
transition period on May 26, 2020 and May 26,
2022, respectively.EMA distinguishes among medical devices:
combination products, medical devices with an
ancillary medicinal substance, companion di-
agnostics, medical devices made of substances
that are systemically absorbed, and borderline
products.2 Examples of these categories can also
be easily recognized among medical devices of
interests for allergology and mentioned in this
paper. All medical devices should firstly pass a
conformity assessment by a notifying body to
receive a Conformité Européenne (CE) mark.
Then combination products (such as drugs
delivered through inhalers) should be treated as
medicines and therefore undergo assessment by
EMA as medicines. Notifying bodies should
consult EMA for medical devices made of
substances that are systemically absorbed and
companion diagnostics. EMA can also be
consulted by the European Commission for
borderline products: medicines or medical
devices.
DEVICES USED FOR ALLERGY DIAGNOSIS
AND MONITORING
Devices for diagnosis of systemic sensitization
Skin prick tests
Skin prick test (SPT) is used to detect systemic
sensitization to airborne and food allergens, and is
used worldwide as first-line diagnostic approach.3–
6 The intradermal test technique is currently
limited to the diagnostic work-up of hymenoptera
venom and drug allergy. SPT elicits in the skin a
visible IgE-mediated wheal and flare reaction that
is specific for the allergen tested. The test requires
that a minimal amount of an allergen extract con-
taining specific components, both genuine and
cross-reacting, to be put into contact with the
dermal mast cells by pricking the epidermis. If the
mast cells carry on their surface the IgE specific to
the component(s) of the allergenic extract, they
degranulate and produce the detectable wheal
and flare reaction. Thus, to perform SPT, the
allergen extract must be put into contact with mast
cells by an appropriate device.
The prick devices should be sterile and for one-
time use. They can vary in terms of material (plastic
or metal), shape (lancet, needle, bifurcated lancet,
with or without guard), number (single or multi-
puncture devices) and can be prepared as pre-
Medical devices in
Allergology
Shared by other
specialists
Routinely established/
experimental Page
Used for diagnosis and monitoring
Allergy skin tests
- Skin Prick tests - Routinely established 2
- Allergy patch tests Dermatologists Routinely established 6
Devices in respiratory allergy
- Pulmonary function devices Pulmonologists Routinely established 7
- Peak expiratory flow meters Pulmonologists Routinely established 8
- Plethysmograpy Pulmonologists Routinely established 8
- Carbon monoxide diffusion Pulmonologists Routinely established 8
- Fractional expiratory nitric oxide Pulmonologists Routinely established 9
- Bronchoscopy Pulmonologists Routinely established &
Experimental
13
- For sputum assessment Pulmonologists Routinely established &
experimental
13
- Exhaled breath condensate Pulmonologists Experimental 13
- Exhaled breath temperature Pulmonologists Experimental 13
- Oscillometry Pulmonologists Experimental 14
- For ‘-omics’ reasearch Pulmonologists Experimental 13
- Nasal resistance Otorhinolaryngologists Experimental 9
- Peak nasal respiratory flow Otorhinolaryngologists Routinely established &
experimental
9
Devices aimed at allergen avoidance
- Devices reducing indoor
allergens
- Routinely established 10
- Breathing masks Pulmonologists Routinely established 10
- Nasal filters Otorhinolaryngologists Routinely established 11
- Mucosal barrier devices Otorhinolaryngologists Routinely established 11
Devices for mobile health
(mHealth)
11
- Devices for self-assessment Pulmonologists Routinely established &
Experimental
12
- Devices for treatment assessment Pulmonologists Routinely established &
experimental
12
(continued)
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Medical devices in
Allergology
Shared by other
specialists
Routinely established/
experimental Page
Used in treatment
Devices for drug delivery in
asthma
14
- Pressurized metered dose
inhalers
Pulmonologists Routinely established 14
- Dry powder inhalers Pulmonologists Routinely established 14
- Nebulizers Pulmonologists Routinely established 15
- Spacers Pulmonologists Routinely established 15
Nasal drug delivery devices 16
- Dropper delivery device Otorhinolaryngologists Routinely established 16
- Metered-dose pump sprays Otorhinolaryngologists Routinely established 17
- Exhalation delivery desystems Otorhinolaryngologists Experimental 17
Energy fields using devices 17
- Rhinophototherapy Otorhinolaryngologists Routinely established &
Experimental
17
- Laser therapy Otorhinolaryngologists Routinely established &
Experimental
18
- High intensity ultrasound therapy Otorhinolaryngologists Experimental 18
- Radiofrequency turbinoplasty Otorhinolaryngologists Experimental 18
- Acupuncture & herbal
moxibustion
Otorhinolaryngologists Routinely established 18
Devices for anaphylaxis management
- Autoinjectors - Routinely established 18
Table 1. (Continued) Medical devices used in allergy diagnosis and treatment, shared with other organ specialists
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obviously, no liquid extract solution is needed, and
the device directly pricks through the skin. Obvi-
ously, there are numerous manufacturers world-
wide producing SPT devices, and it is not possible
to have an exhaustive list of all of them. The ma-
jority of devices have a “guard” around the sting-
ing point that avoids an excessive penetration
through the epidermis, limiting the puncture depth
to 1 mm. If needles without guard (eg, 23G or in-
sulin syringe needles) are used, the risk of a too
deep puncture increases.
SPT is largely operator-dependent;4,7–9 thus it
must be performed by well trained personnel. Allthe material used must be sterile, and one device
for each single allergen must be used (except for
the case of multiple-site devices).4,5 In the
commonly used procedure, a drop of the extract
is placed on a marked part of the skin; then the
device is pushed through the drop and
epidermis until the dermis is reached. The SPT
procedure should not evoke bleeding.6 If
positive, a wheal and flare reaction appears after
10–20 min, which is typically accompanied by
local itching. The most common causes for false
negative results are insufficient depth of the prick
(so that dermis is not reached) or interference by
drugs (most often antihistamines). Causes of false
positive results are excessive pressure
Diagnosis/treatment of structural and
functional pathologic features Medical Devices
IgE-mediated sensitization Skin Prick Test (SPT) devices
Intradermal test (ID) devices (only for drug allergy
and hymenoptera allergy)
Type 4 sensitization Atopy patch tests
Patch test for contact sensitivity
Airway pathology and function Portable respiratory measurement instruments
Plethysmograhy and CO diffusion
Pressurized metered dose inhalers, Dry powder
inhalers
Bronchial inflammation Bronchoscopy
Induced Sputum
Fractional Exhaled Nitric Oxide (FeNO)
Exhaled breath condensate, Exhaled breath
temperature
Nasal function and underlying pathologic
mechanisms
Peak Nasal Inspiratory Flow (PNIF)
Nasal Cytology
Rhinophototherapy, Laser-therapy, Phototherapy
Anaphylaxis Adrenaline autoinjectors
Devices to avoid allergens Masks
Nasal filters
Barrier enhancing medical devices
Table 2. Diagnostic and therapeutis medical devices classified in terms of the specific pathologic processess they are applied for PMDI:; DPI:
r
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dermographism.4 For those reasons, the SPT is
considered highly tester-dependent.
The influence of the specific characteristics of a
given device on the results of SPT has been dis-
cussed in the literature, but well-designed studies
comparing different devices are few, and the re-
sults are not conclusive. Fatteh et al compared the
SPT results obtained with different devices and
reported significant variability among the devices
tested.7 Warner et al found significant differences
for all aspects of device performance for all
devices they assessed, and also noted that multi-
headed devices had a significant intra-devicevariability and were more painful than single-
prick devices.10 In this study, multi-headed de-
vices had larger reactions when applied on the
back, whereas single devices had larger reactions
on the volar surface of arms. One study showed
that metal lancets and syringe needles were su-
perior in sensitivity to other devices.11 Again,
another study evaluated the influence of the
weight of the devices used (lancets and needles)
and concluded that lighter devices could provide
more reproducible results.12 A meta-analysis
focusing the diagnostic accuracy of SPT included
7 studies.13 The pooled estimate of sensitivity and
specificity for the test was 88.4 and 77.1%,
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the devices used. Of note, it was shown that the
SPT devices passing through the drop of allergen
extract were equivalent in sensitivity and
specificity to the pre-coated lancet (no descrip-
tion was provided of the device used).14 In
children, it was clearly shown that the puncture
technique (with or without rotating the prick
device at puncture) modifies the results, thus
highlighting the relevance of the technique.15
When intradermal tests and a multi-head device
(Multi-Test II ) were compared, no clear difference
in the performance could be established.16 In
another open not randomized study the multi-
head SPT had a comparable performance as the
dilutional intradermal test.17
In addition to the device- and operator-
dependency of SPT, the concentration/potency of
the allergen extract should be taken into account.
There is still a wide variability in the allergen con-
tent and the presence of major allergens among
commercial extracts, which may contribute to the
level of reproducibility and variability of the SPT
results.18–21
Concerning the safety of the procedure, the risk
of systemic adverse events is extremely low. In fact,
systemic reactions have been described mostly
with scratch and intradermal tests (in particular
with drugs or crude food). The estimated occur-
rence of severe anaphylaxis is less than 1 in 50,000
subjects, with a still lower rate of fatal cases.22–25
Thus, according to the available literature and
case reports, it is suggested that for SPT
execution (independent of the device used) only
the first-line precautions have to be observed.26
SPT remain the first-line diagnostic approach for
IgE sensitization. Its value resides in the best cost/
benefit ratio, rapidity of response, concordance
with biological IgE assays, and safety.4–8,27 Many
different devices for SPT have been proposed
over time, with variable and difficult to interpret
results. It is clear that there are 3 main variability
sources: 1) concentration and potency of the
extract; 2) nature of the device (metal, plastic,
with/without guard, pre-coated, etc); 3) opera-
tors’ skill. Looking at the available literature, it is
not possible to identify a SPT device as the gold-
standard. The recommendation is that each oper-
ator should use, when possible, the sameallergenic extracts and the same type of devices.
Also, a proper and detailed training in the use of
SPT is recommended for all healthcare operators,
with a periodic review of the technique.4–7Allergy patch tests
Patch tests (PT) have undergone a long evolu-
tion to still remain the cornerstone of contact
dermatitis diagnosis and the technical aspects of
the method have been quite well refined and
standardized.28–30 The principle of the test is to
evoke a delayed (type IV) reaction after applying
on the skin of the patient alleged allergens so as
to replicate a natural inflammatory response due
to the influx of specifically primed lymphocytes.
The tested substances must remain into direct
contact with the skin for at least 48 h.31–33
The substances to be tested and a negative
control (usually vaseline) are inserted into patches
and applied by occlusion usually on skin free of
lesions on the upper back of the subjects. The site
is chosen in order to have a surface large enough
to test many substances at the same time. The
readings are made at 48 and 72 h after the appli-
cation and the relevance of any positive tests to the
clinical presentation in the individual patient must
be considered. Once placed on the skin, PTs are
usually kept about 48 h; they can be read at that
time-point, or outlined with special markers for a
second reading usually done at 72 or 96 h.34,35
The basic requirements for a patch-test cham-
ber are an inert material applied to a hypoaller-
genic tape for providing good occlusion and
fixation for at least 48 h. The allergenic substances
are embedded in round or square patch chambers
of 8–18 mm size which can be of metallic
(aluminium) or plastic material (polyethylene).31 It
is not clear, according to the literature if the
chambers’ size can affect the accuracy of the
test.36,37 There are different patches usually sold
in blocks of 5 or 10 chambers included in bands
of hypoallergenic adhesive material. When liquid
allergens are used, they sometimes require the
use of a filter paper to retain them. In recent
years, new transparent and water resistant PT
have been introduced.
There are numerous pre-defined standard
panels of substances (professional, cosmetics, de-
tergents) at national or international level (baseline
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gions according to the decisions of local special-
ists’ societies and are revised periodically.33,38–41
PTs can be pre-defined and ready to apply, or
can be prepared ex tempore, chosing only the
substances to be tested. In this latter case, there
are commercial solutions at pre-specified concen-
trations that are mounted in patch chambers.
There ae also individually tailored occupational
series with materials contributed by the patient.42
The allergens are usually diluted in petrolatum,
water, or alcohol and rarely with other materials
(olive oil, acetone). They are applied at low
concentrations that have demonstrated their
efficacy.43 They are deposited with pre-filled sy-
ringes with an estimated amount of 20–25 mg for
solids (9) and 15 mgr for liquids (with micropipette
or dropper).44 There are already pre-charged
commercial PT that are easy to use and save time
(eg, T.R.U.E. Test).45
Although there are many commercialized de-
vices for PT (for review see Jonker et al),34 there
are no studies comparing the devices, per se”;
thus, no experimentally supported
recommendation for chosing a specific device
can be made so far.32,46–48
Atopy Patch Tests are used to study atopic
dermatitis in relation to environmental foods or
allergens. The chambers used are recommended
to be large (12 mm).49
Photopatch tests (PhPT) are used to assess
photosensitivity reactions and are applied in
duplicate on the skin; one of them will be irradi-
ated with UV radiation, usually A (UVA), and the
other will remain non-irradiated.50 These allergens
are usually related to sunscreens, plants, non-
steroidal anti-inflammatory drugs (NSAIDs), and
others that require sun exposure to trigger
dermatitis. Results will be reported as negative
(both negative areas), positive PhPT (when there is
positivity only in the irradiated area), allergic con-
tact dermatitis (when the positivity appears in both
and of equal intensity) and allergic photoagraved
contact dermatitis (when both are positive but with
greater intensity in the irradiated area).
There are many other auxiliary devices used in
patch testing helping the positioning of thechambers and the documentation of the results,
summarized in García-Abujeta.51
Diagnostic devices in respiratory allergy
Devices used for respiratory allergy disorders in
general are used to assess the functional capacity
of different parts of the respiratory system, from
nasal patency to the capacity of alveo-capillary
membrane to provide adequate exchange of
gases between the respiratory and cardiovascular
systems. These devices are more organ specific
than disease specific and are used also in otorhi-
nolaryngology and pulmonology. Because the re-
sults of the measurement done with these devices
are not disease specific, they can be used only to
support the clinical diagnosis and not to make one.
They also can support the management of allergic
disorders, as they are sensitive to change due to
therapeutic interventions. Allergic disorders can
impair the function of the respiratory system in
different ways depending on the part of the res-
piratory system they affect and the type of allergic
reaction.52 Based on the underlying pathology,
different devices can be used either on their own
or in combination to evaluate the state of the
airways from nose to small airways or alveoli.53,54
The most commonly used devices are the
spirometers to assess pulmonary function, while
the ones measuring nasal patency are least
commonly used, most probably because of the
poor correlation with the clinical presentation.55
Pulmonary function test devices
Pulmonary function test devices, or spirometers,
are medical devices that measure dynamic lung
volumes and flows by recording the changes in
volume over time during maximal (forced or slow)
inspiration and expiration. There is a high degree
of standardization prescribed by the leading pul-
monology societies, the European Respiratory So-
ciety (ERS) and the American Thoracic Society
(ATS), for the technical characteristics of the de-
vices, the maneuvers of inhalation and exhalation,
and the proper assessment of the measure-
ment.56–58 The devices use different techniques to
measure volume over time: 1) direct measurement
of volume, and 2) indirect measurement of volume
by measuring the flow using different techniques.
Either way a calibration to a standardized volume
(3L) is needed. Flow can be measured using: 1)
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barrier (the so called resistance net), 2)
ultrasound, or 3) a propeller device; the last one
can be used as a pre-calibrated single use part
for the spirometer.57,59 These devices measure 3
volumes: tidal volume (VT), inspiratory reserve
volume (IRV), and expiratory reserve volume
(ERV), the sum of which give the vital capacity
(VC) or forced vital capacity (FVC), depending on
the maneuver used — slow or forced expiration.
When using a forced maneuver, the forced
expiratory volume in 1 s (FEV1) is also calculated
as the measure of obstruction. As the flows are
also measured, standardized flows are also
calculated: peak expiratory flow (PEF), and forced
expiratory flows (FEF) at 25%, 50%, and 75% of
FVC.57 After assessing the technical validity of
the measurement, the results are then compared
with the reference values, GLI, and expressed as
z-values and percentage of a predicted
normal.60,61 Two distinctive pathological patterns
are recognized based on this: obstructive and
restrictive.60 Obstructive pattern is a
characteristic of allergic asthma, but can be
present also in allergic alveolitis.62 As asthma is
characterized with reversible obstruction,
spirometry can be used in combination with
short- or long- acting bronchodilators or
corticosteroids to do a pharmacodynamics test or
as a monitoring tool to assess the effectiveness of
treatment or disease control.63 Pulmonary
function testing is also recommended in patients
with allergic rhinitis or other allergic disorders
(atopic dermatitis or food allergy), because up to
30% of patients suffering from these conditions
may also have unrecognized asthma.64 With the
advances in technology, pocket, handheld, and
smartphone supported devices (spirometers) are
available on the market for a reasonable price to
be used for home monitoring, but they can be
used in highly compliant patients, although more
standardization is needed.59,65 When a restrictive
pattern is present, further diagnostics (body
plethysmography and/or CO diffusion) are
recommended.60Peak expiratory flow meters
Peak expiratory flow meters are simple, hand-
held personal devices that measure the maximal
peak expiratory flow (PEF) that represents just asingle point of the flow-volume curve recorded
during forced spirometry.57,66 PEF results are
expressed in L/min and reflect the airway patency
mostly associated with the large conductive
airways, and only in a small proportion of the
mid-airways; they also account for the strength of
the expiratory muscles which exert extrathoracic
pressure of the airways.7 PEF is highly associated
with the level of effort, so reliable results can be
expected from adherent and compliant
patients.66,67 PEF-meters can be used both to
support the diagnosis of asthma and for monitoring
purposes. It is also recommended as the part of the
Asthma Action Plan (AAP) to assess risk of exacer-
bations and for treatment adjustments to preserve
and maintain control of the disease.63,66,68 Once
individual patients establish their personal best
result, green, yellow and red marks can be added
on the scale of the devices, allowing self-
assessment of the need to updose the treatment
or to seek medical advice in accordance with the
written AAP.63,66 There are both mechanical and
electronic devices present on the market, the
latter storing the separate attempts in digital
format for review by the consulting physician.67Plethysmography – carbon monoxide diffusion
Body plethysmography and carbon monoxide
(CO) diffusion measuring devices assess additional
lung function parameters like static lung volumes
and capacities: residual volume (RV), total lung
capacity (TLC), functional residual capacity (FRC).
They use 2 different methods to evaluate the
restrictive pattern suggested on spirometry.69,70
The downside of both methods is the expensive
equipment and the need for highly specialized
and trained staff, confining them to tertiary
healthcare level premises. Another limitation of
body plethysmography is that it measures all the
air in the chest, thus overestimating the TLC,
especially in aerophagia; conversely CO diffusion
underestimates TLC in severe airways obstruction
or when non-ventilated or poorly ventilated areas
in the lungs exist.69 These shortcomings derive
from the methods of measurement. Body
plethysmography uses the principle of Boyle-
Mariotte to assess FRC by calculating it from the
volume of gas in the body box, the pressure in the
body box, and the pressure at the mouth (repre-
senting alveolar pressure) on the level of FRC
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chanical properties of the lung and airways —
resistance and compliance.71 A proper
assessment of RV is crucial to distinguish
between real restriction (loss of lung volume) and
hyperinflation (increase in RV due to obstruction,
primarily on the level of small airways).60 CO
diffusion measures TLC using the dilution of an
inert gas (helium or methane) along with a low
concentration of CO.70 This mixture is inhaled
from the level of RV (after complete exhalation)
to the TLC. Expired concentration of the inert gas
is measured with the fall in concentration being
proportional to the RV.70 The method
additionally measures the fall in CO
concentration after the breath hold of 10 s when
CO concentration additionally decreases (besides
dilution) because of diffusion through the alveo-
capillary membrane, thus providing the informa-
tion about the diffusion capacity of the lungs.70,72
Diffusion capacity can be significantly decreased in
allergic alveolitis, and CO diffusion represents a
significant part of the diagnostic process in this
disorder.62Nasal resistance/peak nasal inspiratory flow
Nasal patency can be assessed using different
techniques, all of which have a significant short-
coming: they lack significant association with the
clinical presentation, ie, the pathological signs and
symptoms.55,73,74 This is the reason why they are
seldom used in clinical practice and are rarely
used in clinical trials. Basically, 3 different types
of devices are used to assess nasal patency:
rhinomanometers, acoustic rhinometers, and
peak nasal inspiratory flow (PNIF)-meters.73–77
The first two instruments assess each of the
nostrils separately, while PNIF provides an
integral result for both nostrils at the same time.
The shortcoming from assessing the separate
nostrils is based in the nasal cycle that changes
the dominating nostril every 2–4 h significantly
changing the nostrils’ patency in turns. This can
also be because of the change of the posture.78
A confounder with the PNIF could be the
collapse of the alae nasi during forced
inspiration.55,77 Rhinomanometry can be anterior
or posterior, and it uses 1 blocked nostril as a
sampling site for pressure and measures the flow
from the active one that the patients breathethrough during the measurement, repeating the
procedure with the alternative nostril. The
resistance is calculated based on the flow
measured at a standardized pressure for each
nostril. Calculating the total nasal resistance is a
way to overcome nasal cycle changes because
the total nasal resistance stays approximately the
same even during the nasal cycle change.75
Acoustic rhinometry uses sound waves and their
rebounding to assess the cross-sectional area
and length of the nasal cavity, thus providing in-
formation on its structure and dimensions. The
problem is the low level of standardization of this
method.75 PNIF is a cheaper handheld device that
can be used for daily individual measurements but
is rarely used in routine practice.55,77 The latest
study confirmed the low association between
PNIF and the levels of baseline nasal symptoms
assessed by a validated questionnaire, but on the
other hand showed a comparable measure of
clinically significant change after intervention.79
Most recently, visual analog scale (VAS) was
validated to assess the severity of the nasal
symptoms, and a mobile app on a smart phone
can now be used to guide management of
allergic rhinitis.80Fractional expiratory nitric oxide
Nitric oxide (NO) acts as a bronchodilator and is
produced in highest quantities from the nasal mu-
cosa from paranasal sinuses having a significant
role in the homeostasis of the respiratory system.81
It has also been shown that NO production could
be significantly increased by inducible NO
synthase in association with allergic/eosinophilic
inflammation.82 NO production can also be
suppressed in certain conditions, like cystic
fibrosis (CF), primary ciliary dyskinesia (PCD), or in
untreated gastroesophageal/laryngopharyngeal
reflux disorders.83 The commercial devices
measure fractional exhaled nitric oxide (FeNO)
using a higher precision chemiluminescence
method and an electrochemical method, smaller
and less expensive devices, requiring, though,
consumables. The measured FeNO concentrations
are rather low, in part per billion (ppb) and
require careful calibration of the devices. The
measured level of FeNO is dependent on the flow
rate during exhalation, so an ATS/ERS standard of
expiratory flow rate of 50 ml/s is recommended
10 Popov et al. World Allergy Organization Journal (2020) 13:100466
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used to assess the fractions originating from
different parts of the airways, but for now only for
research purposes. The devices are well
standardized and regularly used in clinical
practice.85 Some devices are modified to
measure nasal FeNO, and also FeNO in air
sampled from non-cooperative or patients on
assisted ventilation.84,86 These devices can be used
to support the diagnosis of allergic/eosinophilic
inflammatory disorder (asthma, allergic rhinitis), to
monitor/guide the adherence and effectiveness of
treatment, and for screening of patients with CF
and PCD on the basis of a negative result.83,86,87DEVICES AIMED AT ALLERGEN
AVOIDANCE
Allergen avoidance as a fundamental approach in
allergology
Allergen avoidance is one of the cardinal prin-
ciples in the management of allergic diseases.88
This involves any measures taken to minimize the
contact between the allergens of the ambient
environment and respective mucosal surfaces
and skin of the human organism. The approaches
to achieve this goal range from simple cleaning
methods to reduce the dust and allergen levels
indoors, to filtration and ventilation systems of
residential and office buildings.89 Universal
appliances and reagents used for trivial
household hygiene do not pertain to the
category of medical devices, as opposed to the
specifically tailored tools and non-
pharmacological compounds used to protect
subjects with sensitization to indoor and outdoor
allergens.
Medical devices used to mitigate the effects of
indoor allergens
House dust is invariably present in all dwellings.
Its ubiquitous components are different species of
live mites and their metabolites, moulds, fungi,
cockroach, and pet (where relevant) allergens
which cause allergic sensitization and subsequent
clinical symptoms of asthma, rhinitis, or atopic
dermatitis in predisposed subjects.90–92
Interventions aiming to eliminate house dust
mites or to reduce exposure to their antigens are
usually centered at bedrooms, where mites findoptimal temperature, humidity, and food (human
epithelia) for their development in the beds and
the associated linen/beddings. The methods
used to this end comprise general measures to
reduce indoor relative humidity through
ventilation,89 removing allergen carrying
materials from floors and furniture (including
fluffy toys), vacuuming with HEPA (High Efficiency
Particulate Air) filters,93 ionizers,94 freezing and
hot washing (55 C), spraying with acaricides.95
While all of these interventions bring about
indoor allergen reduction, little clinical benefit
has been achieved with any one of the separate
methods in sensitized subjects. Therefore, it has
been recommended that patients do not resort
to a single preventive method aimed at reducing
allergen exposure.96
Most devices used for allergen elimination are
not specifically designed for the allergy practice.
Among those, which are actively promoted for
direct sales to subjects with asthma, allergic
rhinitis, and atopic dermatitis for use in their
homes as individual medical devices, are bed-
dings made of fabrics, meant to impede the
development of mite colonies. There is an industry
manufacturing impermeable covers and encasings
of matrasses and pillows whose fabric and zippers
would not let through dust mites, their metabolites
and eggs.97 Despite the controversies about their
clinical usefulness, these products maintain a
steady presence on the medical devices’ market
as evidenced by the long list of companies
selling them on Internet.Breathing masks
Covering the face with handkerchiefs, scarves,
and veils is the simple-most instinctive way of self-
protection from any visible or perceived air-born
hazards that may penetrate the airways. Histori-
cally, cloth masks attached over the mouth and
nose were worn on mass scale as a (questionably
effective) protective means during the global
influenza epidemics in the twentieth century. Still
now medical staff and patients wear disposable
cloth masks, also known as "medical" or "hygiene"
masks, to cut the likelihood of contracting or
passing on air-transmitted infections.98 In the last
decades face masks became increasingly popular
first in Asia, but subsequently spreading
elsewhere, as a means against air pollution.
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fibrous material (cotton, microfiber, woven cloth,
plastic, or even paper) meant to trap allergens,
particulate matter, microbes, and gaseous
irritants. In addition, masks can also temper the
inspired air and thus prevent attack of cold and
dry air induced bronchospasm. The more
sophisticated models containing special
cartridges and valves can retain also fine particle
of less than 2.5 mm and also some gaseous
components.
It is conceivable that breathing masks could be
protective against allergens. Surprisingly, there are
not many studies testing how effective masks are
against common outdoor allergens like pollens.
Actually, a study on subjects with Japanese cedar
pollinosis found a statistically significant decrease
in clinical symptoms despite the fact that the
number of pollen particles in the nasal cavity and
on the conjunctiva was unchanged by wearing a
facemask and eyeglasses.99 By all means, face
masks can provide protection of the airways and
conjunctiva in different occupational settings.
Specifically designed studies are required to
characterize the efficacy of a given model of a
breathing mask in reducing the amount of
inhaled allergens and the clinical symptoms.
Nasal filters
In essence, nasal filters are meant to sieve away
particulate matter when inhaled through the nose.
Their key component is a membrane that removes
particles by means of interception and impaction,
which is placed in each nostril's anterior vestibule
and kept in place by a frame.100 They are
disposable and are engineered in a way so that
the inevitable increase of air resistance across the
filtering membrane is below the level of
perception of the subject. Nasal filters act as
invisible breathing masks confined to the nose
and still have to prove their utility and benefits
like clinical effectiveness, convenience, comfort,
and safety at acceptable cost.101,102
Mucosal barrier enhancement devices
Barrier-enforcing measures protecting the nasal
mucosa and blocking contact with potentially
harmful substances such as allergens and particu-
late matter can be implemented: these may be
viewed as a means to achieve allergen avoidance,and, arguably, that all patients may be recom-
mended to use such an approach.103 Ideally, if
implemented properly, this strategy could make
the use of any other therapeutic action unnec-
essary. Attempts have been made to use different
substances as barrier enhancers. These include
cellulose derivatives,104,105 white vaseline,
allergen blocker creams,106–108 lipid based
ointment,108 microemulsion,109,110 liposomal
formulation,111 and seawater gel.112 Many of the
listed approaches had not progressed to the
stage of commercialization. Among these, a
powder microcrystalline hydroxypropyl-
methylcellulose formulation has been developed
into a patented medical device and backed up by
over 20 clinical studies.113 However, not all
derivatives from the broad variety of cellulose
derivatives can offer nasal protection as
demonstrated by a liquid nasal spray, which was
not proven efficacious in a nasal challenge test
model.114MOBILE APPROACHES (MHEALTH)
We are witnessing an amazing technological
development that can be referred to as a “mobile
revolution; it is characterized by a widespread use
of connected mobile devices such as smart-
phones, tablets, and laptops. These tools are
modifying many aspects of our lives including
health care. “Mobile-health”, or “mHealth”, refers to
this set of mobile health applications, and the
World Health Organization (WHO) has stated that
mHealth has the potential for changing the overall
process of healthcare worldwide.115 The
availability of powerful processors, ever-growing
memory capacity, user friendly tools, and pene-
tration of the Internet in all populated areas across
the globe have given rise to a new health culture
and behaviors and allow the monitoring, storage
and sharing of clinical data, promoting self-
assessment and altering patient/physician
communication.
These processes lead to a radical change in the
diagnostic algorithms and in the long-term man-
agement of chronic diseases.116 It is envisaged
that current procedures and services will be
reconsidered, leading to a greater
appropriateness at all stages of the healthcare
process. The above mentioned evolution is in line
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(precision medicine), that includes a tailored
action based on individual genetic pattern and
clinical data.117Self-assessment
Mobile applications (known by the abbreviation
“apps”) for health are software created for smart-
phones and tablets, whose function is to monitor
the symptoms and clinical parameters, allowing
patients to check their health status. They also
improve patients’ adherence to treatment and
enhance their communication with healthcare
providers or physicians. The results of a recent re-
view showed that in 2018 there were 325,000
mobile health apps available to smartphone
owners worldwide with an additional 200 health
apps being launched daily.118
Many wearable devices (bracelets, watches,
bandages, bands) detect through the use of spe-
cial sensors specific physical parameters (ie, heart
rate, respiratory sounds), level of physical activity
(ie, number of steps performed, hours of inactivity),
sleep (hours of sleep, REM sleep, nocturnal awak-
enings, snoring), and allow self-monitoring of
biological parameters in daily life in a passive and
non-intrusive manner.119 Furthermore, wearable
sensors allow matching exposure to
environmental triggers (ie, pollutants or
allergens) to the patient's physiological data.Mobile-based treatment assessment
Technology is transforming inhalers from tools
for drug administration to instruments of care. The
incorporation of modern electronic components
into inhaler devices is aimed to reduce inhalation
errors, to improve patient adherence, and to
monitor and manage patients’ disease states.120
The first built-in inhaler monitoring technology,
that essentially allowed recording of the inhaler
activation, was developed in the 1980s.120
Developers have pursued different strategies;
while Adherium Smart Inhaler Tracker, able to
store the dates and times of inhaler actuations, is
compatible with several inhaler types, eg.
SmartTurbo, SmartDisk, and SmartTrack
(Adherium), the Propeller Health device was the
first to incorporate Global Positioning System(GPS) functionality, in order use the geo-location to
map potential triggers of exacerbations or the use
of rescue medication due to symptoms. Several
devices, such as Care TRx, Sensohaler,
Inspiromatic, T-Haler, and X-haloHome are
capable of monitoring lung functional parameters
such as peak expiratory flow (PEF) and inhalation
flow and volumetric flow rate and exhaled breath
temperature.
The smart inhalers are provided with dose-
memory and dose-reminder functions with a pos-
itive effect on adherence.121,122 The clinical
benefits of this approach, in terms of reduction of
number of oral steroids bursts and hospital
admissions, have been shown.123
Digital health developments have also shown
great utility in the management of device errors,
and are now able to provide detailed feedback on
patients’ device competence.120 The SmartMist
and MDILog have both included sensing
capabilities to facilitate the assessment of
inhalation technique. The latter one is provided
by an accelerometer for the detection of inhaler
shaking and a sensitive temperature sensor for
the assessment of inhalation. Furthermore,
Amiko is able to monitor loading, inhalation,
inspiratory time, and orientation.124 Inhalation
detection technologies can be used to coach
patients on correct device technique. Apps are
under development which have the potential to
correct inhaler errors with, for example, pop-up
instructional videos based on real-time
measurements.
The above mentioned technologies, along with
other innovative e-health developments, have the
potential to reduce the resource burden on
healthcare systems and provide optimal and
personalized asthma management to patients.125
Technologies and innovations are relevant to
improve public and individual health and they
offer real opportunities to improve chronic disease
management, increase the appropriateness of
treatment choices, and lower costs, keeping the
patient at the center of the care process.
Volume 13, No. 10, Month 2020 13OTHER DIAGNOSTIC APPROACHES
INVOLVING MEDICAL DEVICES
The substantial economic impact respiratory al-
lergies pose on society has prompted intensive
research involving the use of different medical
devices. These devices have been used or specially
developed as part of methods aimed at improving
diagnosis and disease management. Following is a
listing of investigational methods and implicated
medical devices not routinely applied in clinical
practice, with short commentaries on the pros-
pects they offer.
Bronchoscopy
Historically bronchoscopy with biopsies and
bronchoalveolar lavage, eventually combined with
bronchial allergen challenges, made possible the
formulation of the present understanding that a
common feature of all phenotypes of asthma is
airway inflammation driven by different mecha-
nisms defining different disease endotypes.126–128
Nowadays, there are different modifications of the
bronchoscopy equipment combined with
ultrasonography, electromagnetic guidance, and
high resolution imaging techniques, which allow
high precision diagnostic procedures reaching
much deeper in the lung periphery.129 On the
basis of bronchoscopy, bronchothermoplasty has
been developed as a therapeutic method in
severe asthma.129
Sputum
Induction and examination of sputum have been
developed as a non-invasive proxy to the bron-
choscopic methods.130–133 The medical devices
associated with examination of sputum are
nebulizers for induction of sputum with hypertonic
saline solutions and laboratory equipment
including standard and cyto-centrifuges for
assessment of the fluid-phase and cellular compo-
nents of sputum. The sputum associated methods
are time-consuming, expensive, and requiring so-
phisticated lab equipment, so they are mostly
confined to highly specialized centres.
Exhaled breath condensate
Collection and examination of exhaled breath
condensate (EBC) is another non-invasive method
to assess biomarkers deriving from theintrathoracic airway contained in the epithelial lin-
ing fluid.85,134,135 It makes use of collection
devices, the principle of which is passing exhaled
air through a cooling chamber so that the breath
vapor and droplets from the epithelial lining fluid
of the airways containing volatile organic
compounds are sampled during tidal breathing
of the examined subject. After collection, the
EBC samples are further processed to identify
biomarker prophiles useable for the diagnosis
and management of airway diseases.
The "-omics" approach
Genomics, proteomics, metabolomics, and
other "-omic" methods measure compounds of
different specificities contained in the exhaled
breath/EBC and can be referred to as breatho-
mics.136 They rely on different modifications of
liquid chromatography and/or mass-spectrometry
for identification of compounds associated with
different pathological processes in the airways and
the creation of libraries of molecules as well char-
acterized biomarkers.107 The clinical utility of
these molecular approaches has yet to be
demonstrated, as the replicability of the results
obtained from different research teams is rather
low.
Exhaled breath temperature
Measurement of exhaled breath temperature
(EBT) has been suggested as a non-invasive
method to detect inflammatory processes in the
airways as a result of increased blood flow within
the airway walls.137–139 As EBT values are within a
narrow range, the thermometers designed for the
purpose of assessing it need to be precise and
very sensitive. EBT increases linearly over the
pediatric age range and seems to be influenced
by gender, but not by height and body
weight.140 When interpreting EBT in subjects
with alleged airway pathology, the possibilities of
tissue destruction (chronic obstructive pulmonary
disease, cystic fibrosis) or excessive bronchial
obstruction and air trapping (severe asthma)
need to be considered, as these conditions drive
EBT down.141 A prominent advantage of the
method is to assess EBT when patients are in a
steady state of their disease and to use this
“personal best” to monitor them and guide their
treatment. Individual devices outfitted with
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which can be used for personalized monitoring
and disease management by telemedicine.142
Oscillometry
Impulse oscillometry (IOS) is a noninvasive
method, which uses sound waves to measure res-
piratory mechanics.143,144 It is based on the
principle of forced oscillation technique (FOT),
which superimposes sound waves of different low
frequencies upon the breathing maneuver of the
tested subject. The IOS/FOT methods are patient-
friendly since they require minimal cooperation
and thus can be applied in children, very elderly
people, and subjects who are on ventilators. FOT
and IOS measurements use equipment of different
construction and can detect subtle changes in the
small airway function even in the setting of normal
spirometry. A limitation of the oscillometry
methods is the broad variability of the results and
need to further validation.DEVICES USED FOR TREATMENT
Asthma drug delivery by inhalation devices
Drugs delivered through inhalation go directly
to the lungs, by-passing the systemic circulation,
thus achieving a rapid local effect at lower doses
and with fewer adverse events. These benefits have
rendered inhalation therapy a preferred route of
drug administration for many respiratory condi-
tions. In the last 3 decades, all types of devices for
drug delivery by inhalation have evolved and
diversified into a wide array of models incorpo-
rating different concepts. At present, more than
250 inhaler devices licensed for drug delivering in
chronic respiratory disorders. The effectiveness of
the inhaled route of administration is related with
the appropriate choice and correct use of an
inhaler device.145
Pressurized metered dose inhalers
Historically, pressurized metered dose inhalers
(pDMIs) were the first introduced in clinical prac-
tice and are the most commonly used pocket-sized
devices for delivery of fixed doses of aerosolized
drug into the airways. Metered dose inhalers offer
multiple advantages such as portability, no need of
an external power source, and release of fixed-
doses uniformly over time.146A pMDI is a pressurized system comprising in a
metal container a mixture of propellants, flavour-
ing agents, surfactants, preservatives, and active
drug comprising approximately 1% of the total
contents. The drug delivery through the pMDIs
takes place when the mixture is released from the
delivery device through a metering valve and stem
which fits into the design of an actuator plastic
boot. Small changes in the actuator design can
affect the aerosol characteristics and the shape of
the jet plume.146
pMDIs emit the dose at high velocity, which
makes premature deposition in the oropharynx
probable. They require careful coordination of
actuation and inhalation, requiring demonstration,
active training and repeated follow-up by the
attending healthcare professionals. pMDI needs
vigorous shaking in case of suspensions.147 (4)
Classical pMDIs deposit the array of their
droplets mainly in the central airways, so that
only 10–15% of dose is reached to the lung;
devices designed to generate extrafine aerosol
could deliver it more to the periphery.148 Breath
actuated devices have also been launched on the
market, which omit the coordination between
actuation of the device and the inhalation.149Dry powder inhalers
Dry powder inhalers (DPIs) are breath actuated
devices which contain medication in the form of
powder and deliver micronized dry particles with
specified characteristics to the respiratory airways
on inhalation. The energy emitted from the
patient's inspiratory airflow is the driving force for
powder dispersion from the device.150 DPIs are
actuated with the onset of the inhalation and
require minimal coordination on the part of the
patient. When reaching the intrathoracic airways,
the dry powder formulation is subjected to larger
dispersion forces and splits into individual
particles.151 As opposed to pMDIs, which have
similar characteristics despite the different
manufacturers, DPIs are mostly “company-
specific” and follow different inhalation protocols.
Comparative studies have been performed to
outline the differences between the different
models.146 This requires acquiring of special
skills by the patients when using different DPIs. In
general, a faster airflow is necessary for the
increase in the particle split and the stronger
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reaching deeper into the airways. However, a
very rapid airflow may increase the deposition in
the region of oropharynx and thus reduce the
delivery of the drug to the lungs.151 The
performance of the DPI system depends on
performance of powder formulation and the
inhaler device. The modern devices are being
designed for different powder formulations,
single or multiple DPIss.152 In single-dose DPIs,
the dose is formulated inside individual capsules.
The mechanism of a single dose delivery is that the
patient must load the device with 1 capsule before
each administration. The multi-unit dose DPIs have
the advantage that before administration of each
dose it does not have to be reloaded, as it utilizes
the factory-metered and sealed doses packaged
so that the device can hold multiple doses at the
same time.153
Nebulizers
Aerosol therapy-nebulizers transform liquid
drug formulation into aerosol of desired charac-
teristics to be inhaled into the respiratory tract.
They have a role in the treatment of asthma and
have particular value in treating subjects with very
low lung volumes as in severe asthma exacerba-
tions, but also in young children and elderly, in
ventilated, non-conscious patients, and, in general,
in those who are unable to use pMDIs or
DPIs.146,154 Nebulizers contain a medication
reservoir, nebulizing mechanisms, and
mouthpiece or facemask.155 They can generate a
spectrum of droplets (ideally in the range from 1
to 5 mm), the finest of which can reach deep into
the lungs.156 There are 3 main types of
nebulizers: jet-driven, ultrasonic, and mesh-
nebulizers.
Jet nebulizers are the most commonly used
drug delivery devices for pulmonary diseases in
emergency settings, utilizing the gas flow from a
compressor.157 The main issues with jet nebulizers
are the noise that some of them generate, the
requirement for a compressor to generate the
aerosol, and the temperature drop of the liquid
in the nebulizer chamber caused by liquid
evaporation in the nebulized droplets.146
Ultrasonic nebulizers are generally preferred to
jet nebulizers. High frequency ultrasonic waves
generate aerosolized particles through therequired vibration range of (1.2–2.4 MHz) by a
piezo-electric crystal. The vibration mechanism is
then transferred to the liquid formulation, which
further produces a fountain of liquid-drug con-
sisting of larger and smaller droplets. The smaller
droplets are stored inside the chamber of the
nebulizer which is inhaled by the patient. The
larger droplets are recovered into the liquid drug
reservoir.154 Ultrasonic nebulizers are more
expensive and increase the temperature of the
nebulized drug solution; therefore, they are
considered inappropriate to nebulize
thermolabile compounds. They are also less
efficient in nebulizing viscous liquids and
suspensions than jet nebulizers, due to the
reduced force they use, and are, therefore
indicated to nebulize only solutions.146
Mesh nebulizers were developed to overcome
the problems associated with jet and ultrasonic
nebulizers. Mesh nebulizers contain a mesh or a
membrane with a range of perforated micron-
sized openings through which the liquid medica-
tion is forced. The diameter of droplet is defined
by the size of the openings, usually between 1 and
6 mm. These nebulizers produce small-sized parti-
cles compared to jet and ultrasonic nebulizers.
They are portable (work on batteries), produce a
substantial fine particle fraction, and have
increased output efficiency and short treatment
time.155
The liquid formulations used in nebulizers are
less expensive and are easier to develop
compared to pMDIs and DPIs. Different compat-
ible drug solutions can be mixed and nebulized at
the same time. The droplet size and the dose
emitted by a device can be altered by a change in
the viscosity of the solution and that nebulizer
settings should be optimized for each medica-
tion.146On the negative side, nebulizers should be
assembled, loaded with medication, and
disassembled and cleaned every time they are
used.158
Spacers
The space chambers, or spacers, are devices
designed to improve the performance of the
metered dose Inhaler (pMDI) by increasing the
distance between the pressurized device and the
patient's mouth and decreasing the velocity of the
droplets. They also cause evaporation of
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produced by the evaporation of the solvent in the
oral cavity. As a result, spacers decrease the
oropharyngeal droplet impact and deposition,
thus minimizing the ensuing local unwanted ef-
fects. They have been shown to decrease systemic
bioavailability and to increase drug deposition in
the lungs.159 The spacers separate the nozzle of
the pMDI from the patient's mouth with the
larger particles sticking on the walls of the
spacer; subsequently, a smaller amount of drug
adheres to the oropharynx, reducing the possible
side effects.160 The correct use of a spacer
chamber largely solves the common and
potentially critical problem of the lack of
coordination of the activation of the MDI with the
onset of inhalation.161 Most spacers have a valve
system so that air only circulates in the direction
of inhalation, closing when the individual exhales
and thus diverting the exhaled air out of the
chamber;they should be provided with a mask
when used in children under 5 years of age and
in elderly people with difficulties in collaboration/
understanding.162 In acute asthma, treatment
with beta-agonists administered by using spacers
is at least as effective as those administered by
nebulizers.163 The use of spacers remains an
alternative with good cost-effectiveness and in
those patients unable to achieve sufficient inspi-
ratory flow.164 However, the administered dose,
the pulmonary deposition/oropharyngeal
deposition ratio and the dependence on
coordination between activation and inspiration
differ considerably between the various available
spacers.165Choice of optimal inhalation device in asthma
Inhaled corticosteroids are the most effective
drugs used in asthma to control airway inflamma-
tion and reduce bronchial hyperresponsiveness,
reducing the severity of asthma.166 The response
to the clinical therapy in asthma depends on the
patients age and the ability to use an inhaler of a
particular type. Children below 5 years of age
present difficulties for aerosol delivery due to
anatomic, physiological, and emotional
factors.167 Generally, it is important to evaluate
the ability of the patient to use a specific inhaler
or mouthpiece, generate optimal inspiratory
drive, and coordinate breathing when using theinhaler.168 Demonstration and training are of
paramount importance to achieving adequate
inhaler technique, maximal adherence to
treatment and, subsequently, optimal control of
asthma.169,170
Rhinitis: intranasal devices
Nasal drug delivery devices
The nasal cavity is a strategic gateway for drug
delivery in conventional topical pharmacotherapy
of sino-nasal diseases such as allergic and non-
allergic rhinitis and rhinosinusitis, but also for
drugs intended for systemic circulation.171
Optimal nasal drug delivery is hindered partly by
the intrinsic geometry of the nose and its
functional properties, namely the nasal valve and
the cyclic physio-morphological alteration of its
turbinates, respectively. In other words, the in-
congruity between the nasal inlet geometry and
the different nasal plumes causes only a fraction of
the drug to be deposited in the target area.172
Consequently, in vitro and in vivo studies are
required to determine which nasal delivery drug
device (NDDD) optimally matches the drug
formulation, be it a solution, suspension,
emulsion, or powder.173 In general, NDDD
containing topical steroid aerosols are mainly
mechanically triggered (pump sprays).
Infrequently they can be electrically powered (eg,
nebulizer) or gas propellant-driven (eg, atom-
izer).174 A NDDD containing topical steroid
(budesonide) in powder form has been devised
and marketed in Europe for AR, vasomotor
rhinitis, and nasal polyps, but studies suggest no
superiority over its aerosol form in terms of polyp
and nasal symptom scores.175 There is some
degree of dissatisfaction expressed by most
current NDDD users because of their
inconvenient and embarrassing use in public due
to immediate liquid run-off and unpleasant post-
nasal drip down to throat.176 More recently, a
breath powered aerosol formulation of
fluticasone propionate (FP) has been developed
in a bi-directional NDDD that seems to overcome
drawbacks inherent to most nasal sprays (see
below).
Nasal dropper delivery devices
Single-use pre-filled pipettes are NDDDs which
use the “blow-fill-seal” technology and still exist for
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congestants and saline. The drug is prefilled in a
small single use plastic container and is squeezed
directly into the nose under direct vision. Similarly,
drugs can be instilled into the nose from a small
multiple-use glass or plastic canister using a glass
dropper. One advantage is no requirement of any
preservatives due to the aseptic manufacturing
process, but care should be taken not to introduce
nasal secretions and microorganism into the
container by backflow when the pressure is
released. Recently, they have been advocated for
delivering steroid formulation into the middle
meatus of patients with nasal polyps, but they
require the head down position.177,178Metered-dose pump sprays
Metered-dose pump sprays (MDPS) predomi-
nate the NDDD market. As stated previously, the
mechanism is finger-actuated which mounts a
metered dose of nasal drugs in spray form from a
non-pressurized container. In vitro testing confirms
high reproducibility of the generated dose. How-
ever, the deposition pattern of drug particles in the
nose is complex and depends on the physical
properties of the device. Studies suggest most
particles about the anterior 2-cm non-ciliated part
of the nasal vestibule and much of the remaining
particles get past the nasal valve along the floor of
the nose with inadequate dispersion along the rest
of nasal and sinus cavities.179,180 This phenomenon
can be further aggravated by forceful sniffing,
which deploys the drug quickly into nasopharynx.
A fluticasone furoate formulation has been
recently designed in a pump spray with a new
short tip and a side actuated NDDD to minimize
trauma to the nasal mucosa.
MDPS devices generally require preservatives,
typically benzalkonium chloride; however, few de-
vices which use a collapsible bag and a movable
piston design can be devoid of preservatives.
Moreover, such an arrangement enables the patient
to use the spray in any head position, particularly
suitable for patients with neck problems. Other
designs incorporating an air filter into MDPS can
also secure a preservative-free aseptic aerosol.174
As benzalkonium chloride has been regarded safe
for chronic use in the nasal mucosa the additional
cost incurred on relatively sophisticated
preservative-free MDPS seems debatable.181Nasal exhalation delivery systems
Nasal exhalation delivery systems (EDS) are
designed to reliably and effectively deliver medi-
cations, such as steroids, higher and deeper into
the nasal passages than intranasal sprays and can
be adapted to any type of dispersion technology
for both liquids and powders.182 Its unique bi-
directional mechanism causes the patient's
exhaled breath to be directed into a mouthpiece
and instantaneously converted through a sealing
nosepiece into a proportional nasal pressure that
effectively propels the drug beyond the nasal valve
so as to deposit it in high/deep sites in the nasal
passages. Furthermore, when the patient exhales
against the resistance of the mouthpiece, the
positive oropharyngeal pressure elevates the soft
palate and can isolate the nose from the mouth
and lungs, hence minimizing systemic absorption
of the drug whenever swallowed. Also the mech-
anism assures patent communication behind the
nasal septum, allowing air (and drug formulation)
to escape through the opposite nostril — thus, the
name “bi-directional”. Additionally, the design of
the device allows firm sliding of the nosepiece into
one nostril, sealing it firmly and hence expanding
mechanically the narrow slit-shaped part of the
nasal triangular valve.183–185
Recent large scale studies have suggested effi-
cacy and safety of an EDS-fluticasone formulation
(EDS-FLU) in chronic rhinosinusitis patients with
and without polyps, expressed as decreased Sino
Nasal Outcome Test scores as well as improve-
ment in nasal polyp score in majority (60%) of pa-
tients. Recently a 60–70% decrease of the
indication for surgery has been reported following
EDS-FLU use.183,184 Xhance (fluticasone
propionate), which uses this new delivery system,
is currently approved for the treatment of nasal
polyps in adults. It has shown promising results in
adults and is currently undergoing evaluation in
pediatric patients.186Medical devices using energy fields for allergic
rhinitis treatment
Rhinophototherapy
Devices beaming inside the nose certain wave-
lengths of visible and infrared light have been
shown to reduce the symptoms and improve
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outdoor and indoor allergens.187–190
Laser therapy
Attempts of using conventional laser treatment
for allergic rhinitis have been initiated in the 1990s.
The technology has now been refined, and 810 nm
diode laser has been demonstrated to offer relief
of symptoms to allergic rhinitis sufferers when
applied before or during the Japanese cedar
pollen season.191,192
High-intensity focused ultrasound therapy
Devices generating ultrasound with specific
characteristics have been found to be effective in
reducing eosinophil loaded tissues and structures
in the nasal cavity, to reduce inferior turbinate hy-
pertrophy and improve ventilation.193,194
Radiofrequency turbinoplasty
Devices generating radiofrequencies with spe-
cific characteristic have been proposed as alter-
native to conventional surgical approaches
ablating inferior turbinates and improving rhinitis
symptoms.195,196
Acupuncture and herbal moxibustion*
Traditional Chinese medicine uses these ap-
proaches presumably interfering with the ener-
getic state of the nasal tissues to improve
symptoms and HRQoL of rhinitis sufferers and
reduce the recurrence of exacerbation epi-
sodes.197–200
Devices for anaphylaxis management
Anaphylaxis is a severe generalized hypersen-
sitivity reaction that is rapid in onset and may
cause death. Anaphylaxis management is mainly
based on preventing a reaction and treating each
anaphylactic episode.201 Epinephrine (adrenaline)
can be life-saving when administered as soon as
possible once anaphylaxis is recognized, namely in
community settings including schools, workplaces,
and recreational facilities, although several barriers* Moxibustion: from moxa - a flammable substance or material
obtained from the leaves of certain Chinese and Japanese worm-
wood plants, especially Artemisia moxa; it is placed on the skin
usually in the form of a cone or cylinder and ignited.to access this treatment, namely in schools, were
identified.202
When indicated, clinicians should prescribe an
epinephrine (adrenaline) auto-injector (EAI/AAI),
teach how to use it by means of training devices,
and review the procedure in every appointment.
Patients should have a written action plan that
explains how to recognize the symptoms and how
to act in case of anaphylaxis. Any patient who has
an EAI device should seek immediate medical care
for further monitoring and treatment, as the
anaphylactic reaction might have ongoing life-
threatening effects, like a biphasic reaction.203
All over the world there are a limited number of
EAI/AAI, and in more than 2/3 of countries patients
do not have access to them in the local pharma-
ceutical market, namely in low- and middle-income
countries.204,205
Main types of devices (autoinjectors)
The EAI/AAI can be divided into two classes:
true auto-injectors, which when activated, extend a
needle in the thigh and automatically administer
an intra-muscular dose of epinephrine, and pre-
filled single-dose syringes that work similarly to
traditional syringes. The device comes pre-loaded
with a premeasured dose of epinephrine, the
needle is uncovered and inserted in the muscle,
and the patient/caregiver presses a plunger to
administer the medication (eg, Symjepi by Sandoz/
Adamis Pharmaceuticals, in two doses, 0.15 and
0.30 mg).
Two premeasured fixed doses of EAI, 0.15 mg
and 0.3 mg, are currently available (eg, EpiPen
(0.30 mg) and EpiPen Jr (0.15 mg) Mylan/MEDA;
Teva's generic versions of EpiPen and EpiPen Jr;
Auvi-Q by Kaléo (auto-injector available in 0.15 mg
and 0.30 mg doses; when activated, a voice
prompt steps through the administration process);
Anapen 0.15 mg and 0.30 mg auto-injectors by
Lincoln Medical; Jext 0.15 mg and 0.30 mg auto-
injectors by ALK-Abello; and Adrenaclick
0.15 mg and 0.30 mg auto-injectors by Amedra
Pharmaceuticals). In a limited number of countries
there is also available a device with an additional
epinephrine dose of 0.50 mg (Emerade 0.15 mg,
0.30 mg and 0.50 mg by Medeca Pharma).
Although several guidelines suggest that chil-
dren weighing 7.5–25 kg should be prescribed
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30 Kg and adults must receive the EAI with
0.30 mg dose,206–208 recently an additional EAI
approved by the FDA is now available for infants
weighing between 7.5 and 15 kg, with an
epinephrine dose of 0.10 mg (Auvi-Q by Kaléo).
Indications and prescription
The prescription of an EAI/AAI can facilitate
timely epinephrine injection in community settings
for patients with anaphylaxis, and also, under
particular circumstances, in patients with high-risk
to anaphylaxis. EAI are indicated in patients
including those with a history of anaphylaxis who
can be re-exposed to their triggers, such as foods,
drugs, stinging insects, or exercise, and those with
idiopathic anaphylaxis.
The EAI prescription can also be considered
and indicated in patients at increased risk of
anaphylaxis who might not yet have experienced
it, including those with food (for instance patients
with previous history of severe generalized acute
urticaria, that reacted to trace amounts of a food,
or had food allergy and concomitant asthma), and
insect allergy (for instance children with a history of
generalized urticaria after an insect sting), namely
when living in areas with difficult access to emer-
gency medical facilities.
There are no absolute contraindications for
intra-muscular epinephrine use in severe/emer-
gency allergic conditions.
The patients/caregivers must receive sufficient
education/training about EAI use, included in a
written action plan, and the technique must be
reviewed in each appointment and also in the
pharmacy when the device is dispensed.209 Once
again a lot of opportunities for improvement were
identified in the quality of care that must be
provided to these patients,210 and both the
European Medicines Agency (EMA) and the US
Food and Drug Administration (FDA)
recommended several measures, including the
introduction of educational material, to ensure
that patients and caregivers can use EAI
successfully.
The companies that market EAI have been
asked by EMA to develop more effective educa-
tional material for patients, as well as for healthcare
professionals, to ensure their optimal use. Thisincludes a training device with which patients can
practice, audio-visual material to show in detail
how the device is to be used, and a checklist for
prescribers to ensure that sufficient information is
given to the patient before they use the EAI. The
product information of adrenaline auto-injectors
has also been updated with further warnings and
precautions, including a recommendation that
some patients should be prescribed with 2 auto-
injectors which they should carry at all times and
a recommendation for family members, caregivers,
or school staff to be trained on how to use the
auto-injector.211
It is advised not to store EAIs under conditions
of excessive heat or cold (eg, in a car or beach bag
in summer time). Manufacturers recommend
keeping them at 20 to 25 C (68–77 F), with
limited time exposures allowed from 15 to 30 C.
Degradation of the epinephrine solution in EAI can
occur without visible discoloration or precipitates.
It is beneficial to check EAI expiration dates and
renew prescriptions in a timely manner. However, if
the only EAI available during an episode of
anaphylaxis is past the expiration date, it can be
used in preference to no epinephrine injection at
all.30
According to recent investigation, almost all
EAIs are still potent a long time after expiration
date. In a recent study, 80% of the devices tested
at least 2 years after the expiration date still
retained 90% or more of the initial epinephrine
dose, indicating that they were still effective under
the FDA rules that require that an EAI in the expi-
ration date must contain 90% or more of the
epinephrine original labeled dose; after 6 months
of the expiration date all the AIE devices had 100%
of the dose, and 12 months after, the devices still
had 95% of the original dose.212
Although the devices were not used to treat
acute anaphylaxis episodes, these data can sup-
port extension changes in the expiration dating
guidance that is currently of 18 months from the
manufacturing process. Nevertheless, nowadays,
we strongly recommend that patients should use
the EAI as labeled, including with the strict respect
for the expiry date.
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All practitioners in the field of allergology have
the privilege to be broad specialists with the
requirement to be familiar with the subtleties of a
multidisciplinary medical field. This involves
knowledge and skills about the wide spectrum of
medical devices used in daily routine, but also
needed for sophisticated diagnostic purposes and
modern disease management. This is in line with
the necessity to support the transformation of the
health care system into integrated care pathways
for interrelated comorbidities.64 This position
paper of the World Allergy Organization (WAO)
is meant to be the first integral document serving
to provide structured information on medical
devices in allergology. It can be regarded as a
kind manual to help patient-centered care.
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